MedicineNews.net - Medical Updates

Glyxambi, a fixed-dose combination of Empagliflozin and Linagliptin, for the treatment of type 2 diabetes mellitus

The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Glyxambi, intended for the ... read article

Qtern, a fixed-dose of Saxagliptin and Dapagliflozin, for adults with type 2 diabetes mellitus: positive opinion from CHMP

The Committee for Medicinal Products for Human Use ( CHMP ) of the European Medicines Agency ( EMA ) has issued a positive opinion, recommending the approval of Qtern ( Saxagliptin and Dapagliflozin ) ... read article

Efficacy of cinnamon in patients with type II diabetes mellitus

Multiple studies have evaluated the hypoglycemic effect of cinnamon in patients with diabetes mellitus type II, with conflicting results. Differences in baseline body mass index ( BMI ) of patient ... read article

Symptoms of insomnia in psoriasis are directly mediated by pruritus and pain

Psoriasis is an immune-mediated chronic inflammatory disorder which manifests as dermatologic lesions, and psoriatic arthritis in about 30% of cases. Psoriasis is associated with multiple comorbid ... read article

Myalept to treat congenital generalized or acquired generalized lipodystrophy

The FDA ( Food and Drug Administration ) has approved Myalept ( Metreleptin for injection ) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients wit ... read article

Myalept as replacement therapy to treat the complications of leptin deficiency

The Food and Drug Administration ( FDA ) has approved Myalept ( Metreleptin for injection ) as replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients wit ... read article

Second-line drug for type 2 diabetes mellitus: Linagliptin results in less hypoglycaemia, less weight gain and perhaps less cardiovascular risk

A new drug could offer significant advantages over existing treatments for type 2 diabetes mellitus patients who don’t respond to Metformin. The new drug, Linagliptin ( Tradjenta, Trajenta ), results ... read article

Type 2 diabetes: Juvisync, a once-daily therapy for patients who need to lower blood sugar and cholesterol

Merck has announced today that the FDA ( Food and Drug Administration ) has approved Juvisync ( Sitagliptin and Simvastatin ), a new treatment for type 2 diabetes that combines the glucose-lowering me ... read article

Selective serotonin reuptake inhibitors increase risks for elderly

Older people taking new generation antidepressants are at more risk of dying or suffering from a range of serious health conditions including stroke, falls, fractures and epilepsy, a study involving r ... read article

Europe: Linagliptin for treatment of diabetes mellitus type 2 approved

Boehringer Ingelheim and Eli Lilly have received marketing authorization from the European Commission for Linagliptin 5 mg film-coated tablets ( Trajenta ) for the treatment of adults with type 2 diab ... read article

2011 - Diabetes mellitus type 2: FDA has approved Tradjenta

The FDA ( Food and Drug Administration ) has approved Tradjenta ( Linagliptin ) tablets, used with diet and exercise, to improve blood glucose control in adults with diabetes mellitus type 2. Patie ... read article

Latuda for the treatment of patients with schizophrenia

Sunovion Pharmaceuticals has announced that the FDA ( Food and Drug Administration ) has approved Latuda ( Lurasidone HCl ) tablets for the treatment of schizophrenia.Latuda is an oral, once-daily aty ... read article

Diabetes mellitus type 2: restrict the use of Rosiglitazone

The FDA ( Food and Drug Administration ) announced that it will significantly restrict the use of the diabetes drug Avandia ( Rosiglitazone ) to patients with type 2 diabetes who cannot control their ... read article

Two therapies slow progression of diabetic retinopathy

In high-risk adults with type 2 diabetes mellitus, two therapies may slow the progression of diabetic retinopathy. Intensive blood glucose control reduced the progression of diabetic retinopathy com ... read article

Potential increased risk of bladder carcinoma after two years exposure to Pioglitazone, an antidiabetic drug

L’FDA ( Food and Drug Administration ) is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos ( Pioglitazone ), is associated with an increased risk of bl ... read article